A century-old tuberculosis vaccine, Bacillus Calmette-Guérin (BCG), may offer a new and affordable way to prevent Alzheimer's disease. Recent research indicates the vaccine can reprogram the brain's immune system and change key markers linked to Alzheimer's. An Indian neuroscientist is now calling for extensive multicenter trials, especially in India, to confirm these findings and explore BCG's potential as a widespread preventive strategy.
Promising Findings from Recent Study
A small, one-year clinical study, published in Communications Medicine, provides new insights into how the BCG vaccine might protect the brain. Researchers followed 23 adults aged 55 and older after they received BCG vaccination. The study found that the vaccine changed how immune cells behaved, including those in the fluid surrounding the brain and spinal cord.
Specifically, participants without existing Alzheimer's-related changes showed favorable shifts in amyloid-beta biomarkers. Amyloid-beta is a protein known to build up in the brains of people with Alzheimer's. Levels of this protein decreased in the cerebrospinal fluid and increased in the blood, suggesting it might be clearing more effectively from the brain.[deccanchronicle+2]
Dr. Mahesh Chandra Kodali, a senior research fellow at Harvard Medical School and Massachusetts General Hospital, co-led this important study. He emphasized the potential for widespread impact. "If future trials confirm these findings, BCG could represent a scalable, affordable strategy to promote healthy brain ageing," Dr. Kodali told ETV Bharat. The vaccine was well tolerated by participants, with no unexpected safety concerns reported.[deccanchronicle+3]
Dr. Steven Arnold, managing director of the Interdisciplinary Brain Center at Mass General Brigham Neuroscience Institute and a senior researcher on the study, noted the deep connection between the immune system and the brain. "The immune system and the brain may be far more connected than we once thought," Dr. Arnold said. He also highlighted the need for rigorous testing in larger, controlled studies to preserve brain health before significant Alzheimer's disease develops.[gavi+3]
India's Unique Opportunity for Trials
Dr. Kodali believes India is uniquely positioned to lead large-scale clinical trials for the BCG vaccine in Alzheimer's prevention. India has a universal BCG vaccination program, meaning the vaccine is already widely integrated into its healthcare system. This makes it an ideal location to study the vaccine's long-term effects on a large, diverse population. India also faces a rapidly aging population, increasing the urgency for effective Alzheimer's prevention strategies.[deccanchronicle]
The BCG vaccine is well-known for its excellent safety record and low cost, having been used in millions of Indians for decades. This widespread use and affordability make it a highly attractive candidate for a public health intervention, especially compared to the high costs and potential side effects of many current Alzheimer's treatments.[deccanchronicle+1]
How BCG May Protect the Brain
The BCG vaccine is primarily known for protecting against tuberculosis. However, it is also a powerful inducer of "trained immunity." This process involves the long-lasting reprogramming of innate immune cells after they are exposed to certain microbial stimuli. This immune reprogramming can last for months or even years.[deccanchronicle+7]
Researchers believe this trained immunity extends beyond fighting tuberculosis. It may enhance the body's general immune response, making it more effective against other infections and even influencing conditions like type 1 diabetes and bladder cancer. In the context of Alzheimer's, this means the vaccine might be training the brain's immune cells to respond more vigorously to harmful molecules, without increasing inflammation. Chronic inflammation in the brain is a known risk factor for neurodegeneration, so preventing it is crucial.[pharmacytimes+9]
The study suggests that BCG may influence how amyloid-beta is transported, cleared, or redistributed between the brain and the rest of the body. This potential to clear amyloid-beta buildup from the central nervous system could be a key mechanism in preventing Alzheimer's disease. Previous research in animal models has also shown that BCG may reduce neuroinflammation and improve cognitive deficits.[medicalnewstoday+2]
Global Burden of Alzheimer's Disease
Alzheimer's disease and other dementias pose a significant global health challenge. Worldwide, at least 55 million people currently live with Alzheimer's or other forms of dementia. This number is expected to rise sharply, potentially exceeding 152 million by 2050 if no breakthroughs occur. Much of this increase will happen in developing countries.[brightfocus+4]
In 2021 alone, there were nearly 10 million new cases of Alzheimer's and related dementias globally. China, the United States, and India ranked as the top three countries in terms of incidence cases. The disease disproportionately affects older individuals, with the percentage of people with Alzheimer's increasing significantly with age. The rising prevalence underscores the urgent need for effective preventive and therapeutic strategies.[pmc+4]
Next Steps and Future Hopes
While the recent findings are encouraging, researchers caution that this was a small, open-label study. It was designed to explore biological mechanisms rather than definitively prove that BCG prevents Alzheimer's or slows its progression. Larger, randomized, placebo-controlled clinical trials are now essential to confirm these observations and determine if these biological changes translate into meaningful clinical benefits, such as reduced cognitive decline.[gavi+4]
Such trials would rigorously compare BCG vaccination against a placebo in a larger group of participants. The potential for the century-old, inexpensive BCG vaccine to become a widespread preventive tool for Alzheimer's offers significant hope. It could provide a far more accessible and affordable strategy than many current Alzheimer's treatments, especially for countries with large populations and limited resources.
